Biocardia announces us patent on bone marrow derived neurokinin-1 receptor positive (nk1r+) mesenchymal stem cells for therapeutic applications

Sunnyvale, calif., may 09, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the united states patent office has granted patent number 11,642,377: titled, “ bone marrow derived neurokinin-1 receptor positive (nk1r+) mesenchymal stem cells for therapeutic applications”, with a patent term that will expire in 2039.
BCDA Ratings Summary
BCDA Quant Ranking